HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

Impact · against what's priced in

Positive Phase III data for sovleplenib and its priority review by the NMPA significantly increase the probability of commercialization for wAIHA in China. The strong response rate (66% vs 15%) and favorable safety profile create a clear path to revenue growth in a treatment landscape lacking targeted therapies.

HCM+0.70

No priced-in read yet